Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $148000.0.

  • Niagen Bioscience's Cash from Financing Activities fell 8575.55% to $148000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year increase of 59540.45%. This contributed to the annual value of $5.4 million for FY2024, which is 606555.56% up from last year.
  • Latest data reveals that Niagen Bioscience reported Cash from Financing Activities of $148000.0 as of Q3 2025, which was down 8575.55% from $3.7 million recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Cash from Financing Activities peaked at $33.4 million during Q1 2021, and registered a low of -$76000.0 during Q4 2023.
  • In the last 5 years, Niagen Bioscience's Cash from Financing Activities had a median value of $148000.0 in 2025 and averaged $2.9 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 9029189.19% in 2021, then crashed by 130000.0% in 2024.
  • Quarter analysis of 5 years shows Niagen Bioscience's Cash from Financing Activities stood at $63000.0 in 2021, then soared by 12088.89% to $7.7 million in 2022, then crashed by 100.99% to -$76000.0 in 2023, then skyrocketed by 5031.58% to $3.7 million in 2024, then crashed by 96.05% to $148000.0 in 2025.
  • Its Cash from Financing Activities was $148000.0 in Q3 2025, compared to $3.7 million in Q2 2025 and $3.1 million in Q1 2025.